grants_govPAR-28-042
Open
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
- Response deadline
- Nov 16, 2029 Due in 1108 days
- Date posted
- Nov 3, 2026
- Source
- Open notice
Description
The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.
Classifications
- NAICS93.CA1
Documents (1)
- PAR-28-042-Full-Announcement.htmltext/html;charset=UTF-8145 KBNot yet available
Contacts
Similar contracts
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)Due Mar 5, 2029
- NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)Due May 26, 2027
- Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)Due Jan 10, 2028
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Due Feb 8, 2028
- NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food SpecimensDue Apr 1, 2027
- Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)Due Jul 14, 2026